| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 03/04/2009 | CN101379089A Anti-ILT7 antibody |
| 03/04/2009 | CN101378768A Conditioned blood composition and method for its production |
| 03/04/2009 | CN101378749A High dosage of mycophenolic acid (MPA) |
| 03/04/2009 | CN101376910A Use of miRNA genes in systemic lupus erythematosus disease diagnose and treatment |
| 03/04/2009 | CN101376005A Method for configuring cosmetic product for nourishing face |
| 03/04/2009 | CN101375972A Health oral liquid and its preparation |
| 03/04/2009 | CN101375859A Compound composite medicament for preventing and treating iron-deficiency anemia and secondary infection of young stock |
| 03/04/2009 | CN101375850A Application of norisoboldine in preparing medicament for treating autoimmune disease |
| 03/04/2009 | CN101375839A Grifola frondosa polysaccharide soft capsules and preparation method thereof |
| 03/04/2009 | CN101375737A Agent capable of inhibiting harmful substance in cigarette |
| 03/04/2009 | CN100465186C A composition and a method for inhibiting platelet aggregation |
| 03/04/2009 | CN100465173C A selective kinase inhibitor |
| 03/04/2009 | CN100464742C NF-kB activation inhibitors |
| 03/04/2009 | CN100464734C A desensitizing anticarious gel and a preparation method thereof |
| 03/03/2009 | US7498435 One amine is substituted with a fused heterocyclic ring and the other with a fused heterocyclic ring or phenyl ring, e.g., N2,N4-Bis(3,4-ethylenedioxyphenyl)-5-cyano-2,4-pyrimidinediamine; inhibit IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators such as histamine |
| 03/03/2009 | US7498406 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/03/2009 | US7498335 Method of producing an antiangiogenic or vascular permeability reducing effect |
| 03/03/2009 | US7498334 Pyrrolopyrimidines as phosphodiesterase VII inhibitors |
| 03/03/2009 | US7498323 Spiro-piperidine compounds and medicinal use thereof |
| 03/03/2009 | US7498321 17β-carbothioate 17α-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 03/03/2009 | US7498313 Large circular target-specific antisense nucleic acid compounds |
| 03/03/2009 | US7498162 A gene expressed polypeptide is used in food, for treating food allergy |
| 03/03/2009 | US7498157 Polypeptide crystal having a polyhistidine tag added to the C-terminal end; effectors; drug screening for enzyme inhibitors; multiple sclerosis, diabetes, Grave's disease, rheumatic arthritis, AIDS, cancer, immunomodulators |
| 03/03/2009 | US7498153 Chimeric immunogens |
| 03/03/2009 | US7498147 Modulating the activity of one or more elements in the complement/lipid pathway |
| 03/03/2009 | US7498143 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 03/03/2009 | US7498129 Measuring changes in level of antigen recognizable by a monoclonal antibody or antigen binding fragment; monoclonal antibody is produced by hybridoma cell line; decreased level indicates a reduced tumor; diagnosis, cell purification |
| 03/03/2009 | US7498046 Composition for inducing immune response comprising inverted microsomes |
| 03/03/2009 | US7498038 Chitin microparticles and their medical uses |
| 03/03/2009 | US7498032 Methods for treating immune disorders or cancer with anti-CD40 antibodies |
| 03/03/2009 | CA2420222C Orally administered peptides to ameliorate atherosclerosis |
| 03/03/2009 | CA2410880C 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| 03/03/2009 | CA2314453C Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 02/28/2009 | CA2597151A1 Hiv vaccine |
| 02/26/2009 | WO2009025300A1 Peptide capable of binding to immunoglobulin |
| 02/26/2009 | WO2009025239A1 Novel preparation for external use |
| 02/26/2009 | WO2009025117A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | WO2009025116A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009024905A1 Pyridine derivatives as s1p1/edg1 receptor modulators |
| 02/26/2009 | WO2009023955A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | WO2008152421A3 Modification of cytokine levels with glucosylamine compounds |
| 02/26/2009 | WO2008136736A3 Immunoregulatory structures from normally occurring proteins |
| 02/26/2009 | WO2008094222A3 Porphyrin catalysts and methods of use thereof |
| 02/26/2009 | WO2008022761A3 Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders |
| 02/26/2009 | US20090054625 Recombinant protein variants |
| 02/26/2009 | US20090054622 Peptide variants of the tumor marker MUC1 and their application |
| 02/26/2009 | US20090054495 4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide; inflammatory bowl disease such as Crohn's disease or Colitis |
| 02/26/2009 | US20090054488 Isomigrastatin Analogs In The Treatment Of Cancer |
| 02/26/2009 | US20090054486 Polymorphic form xvi of fexofenadine hydrochloride |
| 02/26/2009 | US20090054472 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof |
| 02/26/2009 | US20090054467 Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases |
| 02/26/2009 | US20090054465 N-hydroxyacrylamide compounds |
| 02/26/2009 | US20090054452 Thienopyridine Derivatives and the Use Thereof as Hsp90 Modulators |
| 02/26/2009 | US20090054451 Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity |
| 02/26/2009 | US20090054424 Optically active pyridine derivative and a medicament containing the same |
| 02/26/2009 | US20090054409 [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone, used for treating rheumatoid arthritis in mammals |
| 02/26/2009 | US20090054397 Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 02/26/2009 | US20090054391 An aqueous solution comprising a complex of tellurium oxide with a diol and an ammonium salt, used for stimulating cells to produce cytokines and for treating diseases and conditions responsive to increased production of cytokines, such as cancer, autoimmune, neurodegenerative and infectious diseases |
| 02/26/2009 | US20090054345 Template-Fixed Beta-Hairpin Peptidomimetics With Protease Inhibitory Activity |
| 02/26/2009 | US20090054336 Binding Agent |
| 02/26/2009 | US20090054330 Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection |
| 02/26/2009 | US20090054321 Polypeptides and use thereof |
| 02/26/2009 | US20090054311 Novel Cyclosporin Analog Formulations |
| 02/26/2009 | US20090054301 Hypoallergenic composition |
| 02/26/2009 | US20090053264 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 02/26/2009 | US20090053252 Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 02/26/2009 | US20090053248 Compositions and methods for transepithelial molecular transport |
| 02/26/2009 | US20090053237 Use of penicillin-binding proteins or polynucleotides or antibodies thereof for preventing or treating bacterial infections |
| 02/26/2009 | US20090053234 Methods of Preventing or Treating Inflammatory or Autoimmune Disorders by Administering Integrin ALPHAVBETA3 Antogonists in Combination with other Prophylactic or Therapeutic Agents |
| 02/26/2009 | US20090053231 Optical Disc Apparatus |
| 02/26/2009 | US20090053230 Anti-ox40l antibodies and methods using same |
| 02/26/2009 | US20090053212 Humanized anti-human osteopontin antibody |
| 02/26/2009 | US20090053204 Functional Genomic Pore Assay For Mixed Cell Populations |
| 02/26/2009 | US20090053195 Biomarkers for acute graft rejection |
| 02/26/2009 | US20090053194 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |
| 02/26/2009 | US20090053178 Use of herpes vectors for tumor therapy |
| 02/26/2009 | DE202008000653U1 Zusammensetzung zur Steigerung der Immunabwehr und zur Behandlung von Erkältungskrankheiten Composition for enhancing the immune system and for the treatment of colds |
| 02/26/2009 | DE102007039429A1 Verfahren zur Aktivierung regulatorischer T-Zellen A process for the activation of regulatory T cells |
| 02/26/2009 | CA2696793A1 Novel preparation for external use |
| 02/26/2009 | CA2696701A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | CA2696591A1 Cdh3 peptide and medicinal agent comprising the same |
| 02/26/2009 | CA2696473A1 Small molecule inhibitors of lck sh2 domain binding |
| 02/26/2009 | CA2696027A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | CA2695509A1 Pyridine derivatives as s1p1/edg1 receptor modulators |
| 02/25/2009 | EP2028274A2 An antisense oligonucleotide against the TGF-beta2 gene |
| 02/25/2009 | EP2028266A1 Method of producing lymphocytes |
| 02/25/2009 | EP2028187A1 Human and mouse targeting peptides identified by phage display |
| 02/25/2009 | EP2027867A1 Method and composition for inhibition of tumor growth and enhancing an immune response |
| 02/25/2009 | EP2027865A1 Liposome having lipid membrane containing bacterial cell component |
| 02/25/2009 | EP2027863A1 Intestinal eosinophil-suppressing composition |
| 02/25/2009 | EP2027862A1 Composition for enhancing immune function |
| 02/25/2009 | EP2027157A2 Modified humanised anti-interleukin-18 antibodies |
| 02/25/2009 | EP2027154A2 Immunoglobulin constant region domains with enhanced stability |
| 02/25/2009 | EP2027147A1 Phl p 1 allergen derivative |
| 02/25/2009 | EP2027108A1 Histamine receptor antagonists comprising an azepin core |
| 02/25/2009 | EP2026842A1 N-terminal modified peg-trail, method for preparing and uses thereof |
| 02/25/2009 | EP2026832A2 Cladribine regimen for treating multiple sclerosis |
| 02/25/2009 | EP2026778A2 Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
| 02/25/2009 | EP1716113B1 Ep2- receptor agonists |
| 02/25/2009 | EP1471920B1 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |